ScaleReady Awards G-Rex® Grant to Immuneel Therapeutics

ST. PAUL, Minn., June 10, 2025 – ScaleReady, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has announced that Immuneel Therapeutics has received a $150,000 G-Rex® Grant. This grant aims to bolster process development focused on improving the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

India faces a significant challenge with blood cancer, with approximately 120,000 new cases of lymphoma, leukemia, and multiple myeloma each year. Tragically, about 70,000 people succumb annually to these diseases, impacting countless families and communities. Dr. Lakshmikanth Gandikota from Immuneel Therapeutics emphasized the necessity of a viable manufacturing strategy to provide these innovative therapies to all Indian patients in need. The immediate demand for CAR-T cell therapies is almost 200 drug products per day, a figure expected to rise as these treatments potentially become a primary option. Dr. Gandikota highlighted the transition to the G-Rex platform as a crucial step in meeting this demand and scaling production effectively.

John Wilson, CEO of Wilson Wolf, expressed admiration for Immuneel’s innovative and disciplined approach and noted the significant progress India is making towards achieving widespread CAR-T therapy availability. He emphasized the impact of the G-Rex platform in providing hope to cancer patients across India.

The grant will support Immuneel in process development, qualification, and validation of a CAR-T cell therapy production approach centered on the G-Rex platform. This is expected to significantly enhance the production capacity at their 12,000 square foot GMP facility in Bengaluru, which was inaugurated in 2021 as India’s pioneering integrated cell therapy development center. The grant will also aid in conducting comparability studies essential for transitioning from the current low throughput equipment to a more efficient high throughput G-Rex-based system.

The G-Rex Grant Program by ScaleReady has gained substantial traction, leading to an increase in total award funds from $20 million to $30 million. This initiative is designed to save recipients both time and money by streamlining the process of optimized cell and gene-modified cell therapy manufacturing. To date, 200 grants have been awarded, with over 50 applications pending. Grant recipients can receive up to $300,000 and gain access to expert support from ScaleReady’s consortium of G-Rex Grant Partners. These partners offer cutting-edge tools and expertise in cGMP manufacturing, quality and regulatory affairs, CGT business operations, among other areas.

ScaleReady provides a G-Rex-centric manufacturing platform that is adaptable, scalable, and cost-effective for the development and manufacturing of CGT drug products. Currently, this platform is employed by over 800 organizations and is integral to approximately 50% of CGT clinical trials and five commercially approved CGT drugs.

Wilson Wolf Manufacturing is committed to simplifying CGT therapy research and manufacturing using its scalable G-Rex technology, which is employed globally in diverse CGT applications. Bio-Techne Corporation, a global life sciences company, collaborates with Wilson Wolf to develop tailored products for G-Rex bioreactors.

CellReady, the first G-Rex-centric contract development and manufacturing organization, specializes in cell and gene-modified cell therapy development. Immuneel Therapeutics, based in Bangalore, India, is a leading biotechnology company focused on advancing cell and gene therapies for cancer patients in India and has developed a robust pipeline of CAR-T therapies for various oncology and autoimmune indications.

The collaboration and advancements facilitated by the G-Rex Grant aim to significantly impact cancer care in India, offering new hope and treatment options to countless patients.